Blood‐based biomarkers for Alzheimer's disease

IF 1.3 Q4 NEUROSCIENCES

Progress in Neurology and Psychiatry Pub Date : 2022-10-01 DOI:10.1002/pnp.764

Priyanka Chohan, Mark Dashwood, George Theodoulou, Hannah C. Reed, T. Kuruvilla

引用次数: 54

Abstract

Blood‐based biomarkers for identifying Alzheimer's disease (AD) pathology have been of considerable interest over the past decade and can offer a significant advantage over the currently available and validated cerebrospinal fluid and positron emission tomography biomarkers in terms of cost, invasiveness and accessibility. This review explores the role of three blood‐based biomarkers; plasma amyloid β, tau and neurofilament light chain, and their combination, in the identification of AD pathology and how they may be utilised in clinical practice.

查看原文本刊更多论文

基于血液的阿尔茨海默病生物标志物

在过去的十年里，用于识别阿尔茨海默病（AD）病理的基于血液的生物标志物引起了人们的极大兴趣，并且在成本、侵袭性和可及性方面，与目前可用和验证的脑脊液和正电子发射断层扫描生物标志物相比，该生物标志物具有显著优势。这篇综述探讨了三种基于血液的生物标志物的作用；血浆淀粉样蛋白β、tau和神经丝轻链及其组合，用于AD病理学的鉴定以及如何在临床实践中使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in Neurology and Psychiatry NEUROSCIENCES-

CiteScore

1.70

自引率

8.30%

发文量

期刊介绍： Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.